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MELPHALAN (Compound CB.3025), a nitrogen mustard derivative, was syn-
thesized by Bergel and Stock in 1953. The compound is formed by the con-
jugation of the 2-chloroethyl amino group which is the active mustard configura-
tion with the L isomer of the amino acid phenylalanine. The possibiRty exists
that this compound may be incorporated into the intra-cellular pathways of
protein synthesis, thus transporting the alkylating moiety of mustard into the
cell. The compound has the foRowing chemical structure:
CICH2CH2
/CH2'CH'CO2H
CICH CH 2 2
NH2
p-di-2-chloroethylamino-L-phenylalanine.
Pharmacologically melphalan resembles nitrogen mustard, but it is wen
absorbed when administered by.the oral route. The main toxic effects in man
are similar to those ofthe otheralkylatingdrugs; thus thelymphoid and haemo
-
poietic system, and the gastro-intestinal tract, are particularly vulnerable.
Melphalan is insoluble in water but can be dissolved in an ethylalcohol/propylene
glycol mixture. Its halflife in blood at 37' C. is 105-120 minutes.
Phenylalanine occupies a central place in the synthesis of melanin and it
might be expected that melphalan would exert a major inhibitory effect on
melanoma ceRs and Luck (1956) reported inhibition of the Harding-Passey
melanoma in a small number of mice treated with this drug. Holland and
Regelson (1958) treated 16 patients suffering from mahgnant melanoma with
dosesranging from 0-55mg./kg. to 2-22mg./kg. and notedobjectiveimprovement
in two cases. A series of cases treated by Papac et al. (1958) suggested that the
clrug might be of some value in Hodgkin's disease. Recent work (Speed, D. E.,
1963, personal communication) suggests that about one-third ofmyelomapatients
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respond to melphalan; it has also been stated that response may occur in reti-
culum cell sarcoma, Kaposi's sarcoma, neuro and fibrosarcoma and seminoma.
Creech, Ryan and Krementz (1959) have administered melphalan by isolation
perfusion to patients with melanoma of the extremities.
Method of Therapy
Melphalan was given orally. Twenty-seven patients received 2-0 to 3-0
mg./kg. over a 4-5 day period. Two cases (11, 12) received 10-0 mg./kg. over
4 days. After the initial treatment, maintenance therapy was given to four
patients (I1, 13, 14, 16) the aim being to administer 2 mg./kg. over a 21 day
period.
Clinical Material
Melanomas 2 cases
Burkitt's lymphomas 14,
Chronic lymphocytic leukaemia 1 oil
Lymphomas Reticulum cell saxcoma 3 pi-
Lymphosarcoma
. 1
Hodgkin's disease. 2
Myelomas Solitary 1
Generalized
Kaposi's sarcoma
Anaplastic carcinoma ofpost nasal space 3
The relevant clinical and therapeutic details of the twenty-nine patients re-
ported in this series are outlined in Table 1.
111U8trative Case Report8
Case No. 2
A Kikuyu woman, aged 36 years, admitted complaining ofpain and sweRing
of right orbit, and right nasal obstruction. Examination showed a dark red
tumour occupying right, middle and superior nasal meatus. The right eye was
normal. A firm discrete mass was palpable, occupying the medial and superior
parts of the right orbit, the globe was displaced downwards and outwards. The
right preauricular gland was enlarged, measuring 1 cm. x I cm. There was no
evidence of further spread of the disease.
Treatment.-The right antro-ethmoidal area was explored using a lateral ap-
proach. The tumour was found to invade extensively the right orbit, which was
exenterated together with the right ethmoidal labyrinth and frontal sinus, re-
moval was incomplete about the bony floor of the right anterior cranial fossa.
Histologically the tumour was a melanotic melanoma. Melphalan therapy was
instituted on the fifth post-operative day (DI) as 2-0 mg./kg. (DI-5). Two
further courses of melphalan 2-0 mg./kg. were administered from D40-44 and
from D69-73. The relevant haematological findings are noted in Table I.
Response.-By D16 there was an obvious decrease in the size of the tumour
and the preauricular gland. Improvement continued up to and after the second
course of melphalan. Biopsies were taken on D51 from areas previously known
to be involved by tumour and these were histologically negative. The pre-
auricular gland was no longer palpable. The third course of melphalan was
given because of the nature of the ori-ainal -arowth.ORAL MELPHALAN THERAPY IN ADVANCED MALIGNANT DISEASE 383
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The patient was seen at approximately monthly intervals in the Outpatients'
Department and appeared clinicaUy free of disease for a six-month period. A
biopsy, taken from a small black area 0-5 x 0-5 cm. on the anterior end of the
right cribriformplate noted atthe endofthe 7thmonth, wasreported as melanoma.
The patient declined further treatment.
Case No. II
A five-year-old Luo (African) boy was admitted with huge tumour involve-
ment of both maxillae and the left mandible. An immediate tracheostomy
was required to relieve dyspnoea due to occlusion of both nostrils and downward
displacement of the palate by tumour mass (Fig. 1). Apart from some smaH
enlarged nuchal lymph glands there were no signs of other organ involvement.
Because previous experience suggested that the response to conventional doses
(2-0-3-0 mg./kg.) would not affect the child's desperate state, it was decided to
administer a larger dose. Melphalan, 10 mg./kg., was given over four days
(DI-4). Striking tumour regression had occurred by D4 and this continued until
D18 when there was no clinical evidence of tumour in the nose or mouth (Fig. 2).
Haematological toxicity was maximal between D12 (W.C. 1800; platelets
145,000) and D17 (W.C. 2700; platelets 35,000). Blood transfusions were given
on D20. On D27 recurrence was noted in the left mandible, and as he no longer
showed signs of toxicity (haemoglobin 12-1 g. ; W.C. 8000: platelets 265,000)
it was decided to commence maintenance therapy which would anow the ad-
ministration of 2 mg./kg. over 21 days, i.e. 2 mg. orally daily. On D34 the
spleen was enlarged 2 fingers, and white ceR count was 12,800. On D42 his
peripheral blood suggested an acute lymphatic leukaemia and marrow aspiration
confirmed this. Blood transfusions were given on D42, D47 and D54. The
spleen continued to enlarge until by D47 it occupied the left iliac fossa (Fig. 3).
The maintenance dose of 2 mg. melphalan daily was continued to D56 when the
boy lost consciousness. He died of acute lymphoblastic leukaemia on D59 (see
discussion).
Case, No. 13
A 7-year old Mkamba boy presented with a tumour of the right maxina which
on biopsy was reported as a Burkitt's lymphoma. Other organ involvement was
not evident.
Initial treatment was with chloroterephthalanilide dihydrochloride (NSC.
38280) intravenously 4 mg./kg. daily for 28 days, and 8 mg./kg. daily for 18
days, thisproduced asignificant response. Subsequently the child had at intervals
EXPLANATION OF PLATE
FIG. I.-Case 11. Burkitt's lymphoma. Tumour involvement of three jaw quadrants necessitated tracheostomy on admission.
FIG. 2.-Case 11 on D18. Complete regression of jaw tumour produced by melphalan 10
mg./kg. given over four days.
FIG. 3.-Case 11 on D52. The enlarged spleen is outlined. Note no recurrence of jaw tumours.
FIG. 4.-Case 3 on D 2. Burkitt's lymphoma. The tumours, involving both maxillae,
were resistant to oral methotrexate.
FiG. 5.-Case 3 on DIO. Regression produced by melphalan 2,0 mg./kg. given over four
days.BRITISH JOURNAL OF CANCER. Vol. XVII, No. 3.
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3 courses ofnitrogenmustard, each of I
-0 mg./kg., each course given over a three
dayperiod. The response to these 3 courses of HN2 was dramatic with complete
regression ofthe tumour mass which however recurred again within 2-3 months.
Approximately 13 months after the boy was first seen he was readmitted with an
obvious recurrence. Melphalan, 3-0 mg./kg. was given from DI-5 and main-
tenance therapy of 2-0 mg. daily was admiriistered from D6-28. No response
was noted to this therapy and by D26 the tumour was increasing rapidly in size.
1-0 mg./kg. HN2 was given over the period D28-30 and on this occasion there
was no response. Actinomycin D 75 ug./kg. intravenously was given D65-67
without benefit. The possible significance of the development of resistance to
alkylating agents is noted in the discussion.
Case No. 18
A 9-year old Jaluo (African) girl was admitted with a large ulcerating mass
of glands on the right side of the neck. Examination showed a growth in the
post nasal space (P.N.S.), histologically a reticulum cen sarcoma. The spleen
was just palpable and small glands were evident on the left side of the neck.
Postero-anterior chest X-ray showed shght widening of the upper mediastinum.
Melphalan 2 mg./kg. wasgiven over fourdays (D1-4). Tumourgrowth increased
the neck diameterby one inch between Dl-24. Haematological t'-;oxicity was not
evident up to D28 when the child expired, due to a hilar gland mass producing
an obstructive bronchopneumonia.
Case No. 27
A 70-year old Mkamba (African) man was admitted with a large mass of
glands on the left side of the neck and examination showed a vascular friable
growth in the posterior and left P.N.S. Biopsy material from both areas was
reported as anaplastic carcinoma. Melphalan, 2 mg./kg., wasgiven over fivedays (D1-5). There was no tumour response before death on D19. Death was due to
the effects of marrow toxicity.
DISCUSSION
A-Tumour response in different malignancies
Bitrkitt's lymphoma.-The chnical and epidemiological features of Burkitt's
lymphoma have been fuRy described by Burkitt and O'Connor (1961). This
multifocal disease occurs in children. The characteristic clinical feature of 13 of
the 14 cases reported here was involvement of one or more j'aw quadxants by a
rapidly growing osteolytic tumour (Fig. 1). This tumour responds to alkylating
agents in a manner similar to most lymphomas. The points of difference are the
initial great sensitivity (Fig. 2), the early appearance ofresistance, and the rapid
progress of the disease. These points, together with the presence of an easily
assessable jaw tumour, make this lymphoma a very sensitive test system for anti-
tumour agents.
Fourteen cases (3-16) of this tumour synclrome were treated with melphalan.
Tbxee cases (3, 11, 14) showed a marked regression, and improvement was slight
in two cases (4, 16). Six cases (5, 6, 7, 8, 10, 13) did not respond to therapy, and
two cases (9, 12) died too soon for response to be evaluated. Eight cases (5, 7,388 PETER CLIFFORD, R. A. CLIFT AND J. H. GILLMORE
10) 11) 12) 14) 15) 16) had received no previous therapy, and there was a marked
response in two ofthese cases (I1, 14) ancl a slight improvement in one (I6).
Two cases (3, 4) who had received previous treatment with methotrexate with
.no response had tumour regression with melphalan (Fig. 4 and 5). Two patients
.(8, 13) who had received previous treatment with nitrogen mustard with good
response failed to respond to melphalan. Subsequent treatment with nitrogen
mustard was unsuccessful in these cases.
Our standard therapeutic approach in Burkitt's lymphoma is to administer
two intravenous doses each of 0-5 mg./kg. of nitrogen mustard with an interval
of 48 hours between injections. This produces a markecl but transient regression
in alarge proportion of cases (Oettgen, Clifford and Burkitt, 1962) and the results
with melphalan in doses of 2-0 to 3-0 mg./kg. are inferior to this. However, our
nitrogen mustard dosage produces greater haematological toxicity than 3-0
mg./kg. of melphalan and it is noteworthy that Case 11 had a very marked
regression after 10 mg./kg. ofmelphalan.
The response of this tumour to alkylating agents is usually ephemeral. We
have sometimes noticed that after a large dose of nitrogen mustard the tumours
regress completely and do not recur, but the patient succumbs to tumour subse-
quently developing at other sites. This suggests that there may be a pre-
tumourous stage not susceptible to alkylating agents from which subsequent
tumours may develop. Many of our cases developed terminal aleukaemic
leukaemia (Clift, Wright and Clifford, 1963). For these reasons we decided to
attempt maintenance therapy. It has not yet been possible to evaluate the
results of this.
Other lymphomas (17-23).-Seven other lymphomas were treated. The case
of chronic lymphocytic leukaemia (17) showed some response but died from
broncho-pneumonia on D15. This may have been precipitated by a lowering of
resistance against infection and emphasizes the need for great caution in treating
this condition with alkylating agents. None of the other lymphomas responded
to melphalan. A case of lymphocytic lymphosarcoma (21) had responded pre-
viously to nitrogen mustard but was unaffected by melphalan. A case ofHodg-
kin's disease (23) which failed to respond to melphalan subsequently faided to
respond to large doses ofnitrogen mustard (Table 1).
Anaplastic carcinoma ofpost nasal space.-The characteristics of this disease
as seen in East Africa have been described by Clifford (1961). Our usual treat-
ment for this condition involves theregional use oflarge doses ofnitrogen mustard
(Clifford, Chft and Duff, 1961 ; Duff et al., 1961 ; Clifford et al., 1963). Cases 27
and 28 were deemed too ill for this form of therapy. Case 27 had received no
previous therapy and no tumour regression was achieved with melphalan. There
was significant haematological toxicity. Case 28 had received previous therapy
by regional perfusion with an antimetabolite with no response, and he derived
no benefit from melphalan. The tbird patient (29) had secondary deposits in the
lower lumbar area and melphalan therapy produced some subjective improve-
ment.
Malignant melanomas (I and 2).-The response to melphalan was dramatic
in both cases. They were discharged from hospital macroscopically free from
disease. The remission lasted for tbxee months in Case I and seven months in
Case 2.
Solitary plasmacytoma (24).-This patient had a huge occipital tumour which389 ORAL MELPHALAN THERAPY IN ADVANCED MALIGNANT DISEASE
proved resistant to melphalan. Complete regression was subsequently obtained
with nitrogen mustard 2-5 mg./kg., the pelvic marrow being protected by
abdominal aortic occlusion (Clifford et al., 1963).
Di88eminated myelomatWi8 (25).-This patient's marrow was extensively
infiltrated with tumour ceRs and the platelet count before treatment was only
93,000. Because of this only 1-5 mg./kg. was administered. Severe haemato-
logical toxicity was encountered. There was no tumour response.
B-Toxicity
Ga8tro-inte8tinal.-Diarrhoea and vomiting, thought to be mediated by the
central nervous system, occurred in two cases (13, 25) wbilst the drug was being
taken, but was never serious. Delayed toxicity due to depletion of intestinal
mucosal cells was not encountered even at 10 mg./kg.
Haematological.-Significant haematological toxicity was noted in three
patients (11, 25, 27) and in two cases (25, 27) was responsible for death. It is
noteworthy that two adults aged 53 and 70 died from agranulocytosis after doses
of 1-5 and 2
-5 mg./kg. Twelve children suffering from Burkitt's lymphomagiven
2-0 to 3-0 mg./kg. in a similar manner showed no signs of marrow depression and
one child received 10-0 mg./kg. with only moderate toxicity. The proportion of
body weight represented by active bone marrow decreases markedly with age.
Bierman et al. (1961) has demonstrated that repeated leucapheresis increasing the
amount of active marrow enables larger doses ofnitrogen mustard to be tolerated
with less haematological toxicity. It seems likely that such toxicity is propor-
tional to the dose of alkylating agent related to the weight of active marrow
rather than total body weight. Another variable affecting such toxicity may be
the proportion ofbody weight represented by fat. Haematological toxicity from
alkylating agents in the African is less than that recorded in the hterature derived
from Caucasian experience. This may be due to smaller fat depots in the African.
Other.-Neither neurological toxicity nor alopecia was noted in this series of
cases.
SUMMARY
1. Treatment and response to oral melphalan therapy oftwenty-nine patients
is described.
2. Two cases of melanoma and three cases of Burkitt's lymphoma showed a
very dramatic response. The longest remission lasted seven months.
3. It is suggested that a pre-tumourous stage not susceptible to alkvlating
agents may exist in Burkitt's lymphoma.
4. Some principles of the administration and dosage of alkvlatin agents are
discussed.
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